Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …

The mitogen-activated protein kinases (MAPK) pathway, often known as the RAS-RAF-MEK-
ERK signal cascade, functions to transmit upstream signals to its downstream effectors to …

Despite substantial advances in targeting mutant KRAS, tumor resistance to KRAS inhibitors
(KRASi) remains a major barrier to progress. Here, we report proteostasis reprogramming as …

The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …

Our increasing understanding of cancer biology has led to the development of molecularly
targeted anticancer drugs. The full potential of these agents has not, however, been …

Rapidly developing molecular biology techniques have been employed to identify cancer
driver genes in specimens from patients with non-small cell lung cancer (NSCLC). Inhibitors …

Abstract PI3K/AKT signalling is commonly disrupted in human cancers, with AKT being a
central component of the pathway, influencing multiple processes that are directly involved …

Lung cancer is the most frequent cancer with an aggressive clinical course and high
mortality rates. Most cases are diagnosed at advanced stages when treatment options are …